This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

The Effect of Ketogenic Diet on Malignant Tumors- Recurrence and Progress

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified February 2010 by Tel-Aviv Sourasky Medical Center.
Recruitment status was:  Not yet recruiting
Nutricia Liverpool
Information provided by:
Tel-Aviv Sourasky Medical Center Identifier:
First received: March 15, 2010
Last updated: March 23, 2010
Last verified: February 2010

The aim of the study is, to study the efficacy of the ketogenic diet in delaying or preventing recurrence and tumor growth progression of patients who have been previously treated by concomitant chemoradiotherapy (6 months) for high-grade glial tumors.

It will be an open-label trial of nutritional intervention for up to 1 year. An interim analysis of the data will be carried out to assess safety, compliance and efficacy of the diet. This will be reviewed by both SHS and the Clinical trial team.

Condition Intervention
Malignant Tumors Other: Nutritional support with Standard diet Other: Nutritional intervention with the Ketogenic diet

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)

Resource links provided by NLM:

Further study details as provided by Tel-Aviv Sourasky Medical Center:

Primary Outcome Measures:
  • To study the effect of the ketogenic diet on tumor growth progression and longevity in patients with Malignant glioblastoma.
    This will be done by comparing tumor size by repeated MRI studies (every 2 months)

Secondary Outcome Measures:
  • Quality of life
    Performance scale and quality of life evaluation (Karnofsky and EQ5D scale)

Estimated Enrollment: 40
Study Start Date: March 2010
Estimated Study Completion Date: September 2011
Estimated Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Standard diet: Nutritional support Other: Nutritional support with Standard diet
Nutritional support with Standard diet
Experimental: Nutritional intervention: Ketogenic diet. Other: Nutritional intervention with the Ketogenic diet
Nutritional intervention with ketogenic diet. The Diet plan will be based on each patient individually according to his nutritional needs. Age, weight, activity levels, culture and food preferences are taken in consideration


Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  1. Consenting adults aged ≥ 18 years.
  2. Recurrent or progressive high grade glioma after failure of at least one line of standard oncological treatment.
  3. Gliomatosis cerebri, including patients declining radiation treatment.

Exclusion criteria:

  1. Patients with malignant tumors who are receiving treatment at the time of the recruitment.
  2. Early termination - patients who will wish to stop their participation in the trial will discontinue the ketogenic diet and return to their usual diet.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01092247

Contact: Nachum Vaisman, Prof' 009-972-3-6974807

Sponsors and Collaborators
Tel-Aviv Sourasky Medical Center
Nutricia Liverpool
  More Information

Responsible Party: Faith Takurukura BAppSc. PGDip.Diet. RGN, Clinical Trials Specialist, Research & Development, Nutricia Liverpool Identifier: NCT01092247     History of Changes
Other Study ID Numbers: TASMC-09-NV-0056-CTIL
Study First Received: March 15, 2010
Last Updated: March 23, 2010

Keywords provided by Tel-Aviv Sourasky Medical Center:
Patients with malignant tumors

Additional relevant MeSH terms:
Neoplasms processed this record on September 21, 2017